Astria Therapeutics' (ATXS) Market Perform Rating Reaffirmed at JMP Securities

Key Points

• JMP Securities has reaffirmed a "market perform" rating for Astria Therapeutics, with analysts indicating a consensus rating of "Moderate Buy" and an average target price of $25.00.
• The company recently reported a quarterly earnings of ($0.57) EPS, surpassing analyst estimates, while institutional investors hold approximately 98.98% of the stock.
• Astria Therapeutics' stock experienced a significant increase of 37.1%, with current trading occurring at $11.61.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report)'s stock had its "market perform" rating reissued by equities research analysts at JMP Securities in a research report issued on Wednesday,Benzinga reports.

Several other analysts have also recently weighed in on the stock. Wedbush set a $13.00 price target on shares of Astria Therapeutics and gave the company a "neutral" rating in a research note on Wednesday. Citigroup restated an "outperform" rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Evercore ISI restated an "outperform" rating and issued a $26.00 price objective on shares of Astria Therapeutics in a report on Wednesday, October 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Astria Therapeutics in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $49.00 price objective on shares of Astria Therapeutics in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $25.00.

Astria Therapeutics Trading Up 37.1%

NASDAQ ATXS opened at $11.61 on Wednesday. The firm has a market capitalization of $655.27 million, a P/E ratio of -5.78 and a beta of 0.43. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.52. The firm's fifty day simple moving average is $7.23 and its two-hundred day simple moving average is $5.94.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04. As a group, sell-side analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its position in Astria Therapeutics by 185.8% during the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 3,557 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Astria Therapeutics by 503.7% during the first quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company's stock worth $493,000 after acquiring an additional 76,961 shares during the last quarter. Hsbc Holdings PLC raised its position in Astria Therapeutics by 70.3% during the first quarter. Hsbc Holdings PLC now owns 32,808 shares of the biotechnology company's stock worth $174,000 after acquiring an additional 13,545 shares during the last quarter. GAMMA Investing LLC raised its position in Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after acquiring an additional 7,971 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Astria Therapeutics during the first quarter worth about $553,000. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.